Clinical Profiles and Patterns of Neurodegeneration in Amyotrophic Lateral Sclerosis: A Cluster-Based Approach Based on MR Imaging Metrics

References

1. 1.↵
   1. Chiò A,
   2. Calvo A,
   3. Moglia C, et al

   . Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011;82:740–46 doi:10.1136/jnnp.2010.235952 pmid:21402743

   Abstract/FREE Full Text
2. 2.↵
   1. Fang T,
   2. Al Khleifat A,
   3. Stahl DR, et al

   . Comparison of the King’s and MiToS staging systems for ALS. Amyotroph Lateral Scler Fronttotemporal Degener 2017;18:227–32 doi:10.1080/21678421.2016.1265565 pmid:28054828

   CrossRefPubMed
3. 3.↵
   1. Tramacere I,
   2. Dalla Bella E,
   3. Chiò A, et al

   . The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2015;86:1180–85 doi:10.1136/jnnp-2014-310176 pmid:25886781

   Abstract/FREE Full Text
4. 4.↵
   1. Brooks BR,
   2. Miller RG,
   3. Swash M, et al

   ; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrop Lateral Scler Motor Neuron Disord 2000;1:293–99 doi:10.1080/146608200300079536 pmid:11464847

   CrossRefPubMed
5. 5.↵
   1. Strong MJ,
   2. Abrahams S,
   3. Goldstein LH, et al

   . Amyotrophic lateral sclerosis: frontotemporal spectrum disorder (ALS-FTSD)—revised diagnostic criteria. Amyotroph Lateral Scler Fronteporal Degener 2017;18:153–74 doi:10.1080/21678421.2016.1267768 pmid:28054827

   CrossRefPubMed
6. 6.↵
   1. Balendra R,
   2. Jones A,
   3. Jivraj N, et al

   ; UK-MND LiCALS Study Group, Mito Target ALS Study Group. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry 2015;86:45–49 doi:10.1136/jnnp-2013-306865 pmid:24463480

   Abstract/FREE Full Text
7. 7.↵
   1. Introna A,
   2. Milella G,
   3. Morea A, et al

   . King’s College progression rate at first clinical evaluation: a new measure of disease progression in amyotrophic lateral sclerosis. J Neurol Sci 2021;431:120041 doi:10.1016/j.jns.2021.120041 pmid:34736124

   CrossRefPubMed
8. 8.↵
   1. Balendra R,
   2. Al Khleifat A,
   3. Fang T, et al

   . A standard operating procedure for King’s ALS clinical staging. Amyotroph Lateral Scler Fronteporal 2019;20:159–64 doi:10.1080/21678421.2018.1556696 pmid:30773950

   CrossRefPubMed
9. 9.↵
   1. Bakers JN,
   2. de Jongh AD,
   3. Bunte TM, et al

   . Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures. Amyotroph Lateral Scler Fronteporal 2021;23;500–07 doi:10.1080/21678421.2021.2016838 pmid:34949141

   CrossRefPubMed
10. 10.↵
    1. Gaiani A,
    2. Martinelli I,
    3. Bello L, et al

    . Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol 2017;74:525–32 doi:10.1001/jamaneurol.2016.5398 pmid:28264096

    CrossRefPubMed
11. 11.↵
    1. Scarafino A,
    2. D’Errico E,
    3. Introna A, et al

    . Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J Neurol 2018;265:2353–62 doi:10.1007/s00415-018-9008-3 pmid:30116940

    CrossRefPubMed
12. 12.↵
    1. Verber NS,
    2. Shepheard SR,
    3. Sassani M, et al

    . Biomarkers in motor neuron disease: a state of the art review. Front Neurol 2019;10:291 doi:10.3389/fneur.2019.00291 pmid:31001186

    CrossRefPubMed
13. 13.↵
    1. Grolez G,
    2. Moreau C,
    3. Danel-Brunaud V, et al

    . The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol 2016;16:155 doi:10.1186/s12883-016-0672-6 pmid:27567641

    CrossRefPubMed
14. 14.↵
    1. Agosta F,
    2. Valsasina P,
    3. Riva N, et al

    . The cortical signature of amyotrophic lateral sclerosis. PLoS One 2012;7:e42816 doi:10.1371/journal.pone.0042816 pmid:22880116

    CrossRefPubMed
15. 15.↵
    1. Schuster C,
    2. Kasper E,
    3. Machts J, et al

    . Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study. J Neurol 2013;260:2856–64 doi:10.1007/s00415-013-7083-z pmid:23996101

    CrossRefPubMed
16. 16.↵
    1. Walhout R,
    2. Westeneng H-J,
    3. Verstraete E, et al

    . Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J Neurol Neurosurg Psychiatry 2015;86:288–94 doi:10.1136/jnnp-2013-306839] pmid:25121571

    Abstract/FREE Full Text
17. 17.↵
    1. Mezzapesa DM,
    2. D’Errico E,
    3. Tortelli R, et al

    . Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis. PLoS One 2013;8:e80748 doi:10.1371/journal.pone.0080748 pmid:24278317

    CrossRefPubMed
18. 18.↵
    1. Distaso E,
    2. Milella G,
    3. Mezzapesa DM, et al

    . Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone. J Neurol 2021;268:3307–15 doi:10.1007/s00415-021-10495-9 pmid:33655342

    CrossRefPubMed
19. 19.↵
    1. Senda J,
    2. Kato S,
    3. Kaga T, et al

    . Progressive and widespread brain damage in ALS: MRI voxel-based morphometry and diffusion tensor imaging study. Amyotroph Lateral Scler 2011;12:59–69 doi:10.3109/17482968.2010.517850 pmid:21271792

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Milella G,
    2. Introna A,
    3. Ghirelli A, et al

    . Medulla oblongata volume as a promising predictor of survival in amyotrophic lateral sclerosis. Neuroimage Clin 2022;34:103015 doi:10.1016/j.nicl.2022.103015 pmid:35561555

    CrossRefPubMed
21. 21.↵
    1. Li H,
    2. Zhang Q,
    3. Duan Q, et al

    . Brainstem involvement in amyotrophic lateral sclerosis: a combined structural and diffusion tensor MRI analysis. Front. Neurosci 2021;15:675444 doi:10.3389/fnins.2021.675444 pmid:34149349

    CrossRefPubMed
22. 22.↵
    1. Schuster C,
    2. Hardiman O,
    3. Bede P

    . Survival prediction in amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol 2017;17:73 doi:10.1186/s12883-017-0854-x pmid:28412941

    CrossRefPubMed
23. 23.↵
    1. Finegan E,
    2. Li Hi Shing S,
    3. Chipika RH, et al

    . Widespread subcortical grey matter degeneration in primary lateral sclerosis: a multimodal imaging study with genetic profiling. Neuroimage Clin 2019;24:102089 doi:10.1016/j.nicl.2019.102089 pmid:31795059

    CrossRefPubMed
24. 24.↵
    1. Consonni M,
    2. Dalla Bella E,
    3. Contarino VE, et al

    . Cortical thinning trajectories across disease stages and cognitive impairment in amyotrophic lateral sclerosis. Cortex 2020;131:284–94 doi:10.1016/j.cortex.2020.07.007 pmid:32811660

    CrossRefPubMed
25. 25.↵
    1. Ferrea S,
    2. Junker F,
    3. Korth M, et al

    . Cortical thinning of motor and non-motor brain regions enables diagnosis of amyotrophic lateral sclerosis and supports distinction between upper- and lower-motoneuron phenotypes. Biomedicines 2021;9:1195 doi:10.3390/biomedicines9091195 pmid:34572380

    CrossRefPubMed
26. 26.↵
    1. Bede P,
    2. Murad A,
    3. Lope J, et al

    . Clusters of anatomical disease-burden patterns in ALS: a data-driven approach confirms radiological subtypes. J Neurol 2022;268:4404–13 doi:10.1007/s00415-022-11081-3 pmid:35333981

    CrossRefPubMed
27. 27.↵
    1. Tan HH,
    2. Westeneng HJ,
    3. Nitert AD, et al

    . MRI clustering reveals three ALS subtypes with unique neurodegeneration patterns. Ann Neurol 2022;92:1030–45 doi:10.1002/ana.26488 pmid:36054734

    CrossRefPubMed
28. 28.↵
    1. Cedarbaum JM,
    2. Stambler N,
    3. Malta E, et al

    . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function—BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13–21 doi:10.1016/s0022-510x(99)00210-5 pmid:10540002

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Kimura F,
    2. Fujimura C,
    3. Ishida S, et al

    . Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265–67 doi:10.1212/01.wnl.0000194316.91908.8a pmid:16434671

    Abstract/FREE Full Text
30. 30.↵
    1. Grachev ID,
    2. Berdichevsky D,
    3. Rauch SL, et al

    . A method for assessing the accuracy of intersubject registration of the human brain using anatomic landmarks. Neuroimage 1999;9:250–68 doi:10.1006/nimg.1998.0397 pmid:9927554

    CrossRefPubMed
31. 31.↵
    1. Hutton C,
    2. Draganski B,
    3. Ashburner J, et al

    . A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. Neuroimage 2009;48:371–80 doi:10.1016/j.neuroimage.2009.06.043 pmid:19559801

    CrossRefPubMed
32. 32.↵
    1. Iglesias JE,
    2. Van Leemput K,
    3. Bhatt P, et al

    ; Alzheimer’s Disease Neuroimaging Initiative. Bayesian segmentation of brainstem structures in MRI. NeuroImage 2015;113:184–95 doi:10.1016/j.neuroimage.2015.02.065 pmid:25776214

    CrossRefPubMed
33. 33.↵
    1. Pintzka C,
    2. Hansen TI,
    3. Evensmoen H, et al

    . Marked effects of intracranial volume correction methods on sex differences in neuroanatomical structures: a HUNT MRI study. Front Neurosci 2015;9:238 doi:10.3389/fnins.2015.00238 pmid:26217172

    CrossRefPubMed
34. 34.↵
    1. Steinbach R,
    2. Prell T,
    3. Gaur N, et al

    . Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis. Neuroimage Clin 2021;30:102674 doi:10.1016/j.nicl.2021.102674 pmid:33901988

    CrossRefPubMed
35. 35.↵
    1. Zhang Q,
    2. Mao C,
    3. Jin J, et al

    . Side of limb-onset predicts laterality of gray matter loss in amyotrophic lateral sclerosis. BioMed Res Int 2014;2014:e473250 doi:10.1155/2014/473250 pmid:25093168

    CrossRefPubMed
36. 36.↵
    1. Fabiano AJ,
    2. Horsfield MA,
    3. Bakshi R

    . Interhemispheric asymmetry of brain diffusivity in normal individuals: a diffusion-weighted MR imaging study. AJNR Am J Neuroradiol 2005;26:1089–94 pmid:15891165

    PubMedWeb of Science
37. 37.↵
    1. Bede P,
    2. Elamin M,
    3. Byrne S, et al

    . Sexual dimorphism in ALS: exploring gender-specific neuroimaging signatures. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:235–43 doi:10.3109/21678421.2013.865749 pmid:24344910

    CrossRefPubMed
38. 38.↵
    1. Chiu T,
    2. Fang D,
    3. Chen J, et al

    . A robust and scalable clustering algorithm for mixed type attributes in large database environment. In: Proceedings of the seventh ACM SIGKDD international conference on knowledge discovery and data mining. New York, New York, August 2001:263–68 doi:10.1145/502512.502549
39. 39.↵
    1. Kaufman L,
    2. Rousseuw PJ

    . Finding groups in data: an introduction to cluster analysis. Biometrics 1991;47:788 doi:10.2307/2532178

    CrossRef
40. 40.↵
    1. Spinelli EG,
    2. Riva N,
    3. Rancoita PMV, et al

    . Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis. Neuroimage Clin 2020;27:102315 doi:10.1016/j.nicl.2020.102315 pmid:32593977

    CrossRefPubMed
41. 41.↵
    1. Brettschneider J,
    2. Del Tredici K,
    3. Toledo JB, et al

    . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20–38 doi:10.1002/ana.23937 pmid:23686809

    CrossRefPubMed
42. 42.↵
    1. Schito P,
    2. Spinelli EG,
    3. Malvaso A, et al

    . Primary lateral sclerosis presenting with focal onset spreading through contiguous neuroanatomic regions. Neurology 2022;98:503–04 doi:10.1212/WNL.0000000000200011 pmid:35131910

    Abstract/FREE Full Text
43. 43.↵
    1. Ravits J

    . Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. Exp Neurol 2014;262:121–26 doi:10.1016/j.expneurol.2014.07.021 pmid:25108067

    CrossRefPubMed
44. 44.↵
    1. Sekiguchi T,
    2. Kanouchi T,
    3. Shibuya K, et al

    . Spreading of amyotrophic lateral sclerosis lesions–multifocal hits and local propagation? J Neurol Neurosurg Psychiatry 2014;85:85–91 doi:10.1136/jnnp-2013-305617 pmid:24027298

    Abstract/FREE Full Text
45. 45.↵
    1. Ferraro PM,
    2. Cabona C,
    3. Meo G, et al

    . Age at symptom onset influences cortical thinning distribution and survival in amyotrophic lateral sclerosis. Neuroradiology 2021;63:1481–87 doi:10.1007/s00234-021-02681-3 pmid:33660067

    CrossRefPubMed
46. 46.↵
    1. Angenstein F,
    2. Niessen HG,
    3. Goldschmidt J, et al

    . Age-dependent changes in MRI of motor brain stem nuclei in a mouse model of ALS. Neuroreport 2004;15:2271–74 doi:10.1097/00001756-200410050-00026] pmid:15371748

    CrossRefPubMedWeb of Science
47. 47.↵
    1. Ferraro PM,
    2. Campi C,
    3. Miceli A, et al

    . 18F-FDG-PET correlates of aging and disease course in ALS as revealed by distinct PVC approaches. Eur J Radiol Open 2022;9:100394 doi:10.1016/j.ejro.2022.100394 pmid:35059473

    CrossRefPubMed
48. 48.↵
    1. Trojsi F,
    2. Di Nardo F,
    3. Caiazzo G, et al

    . Between-sex variability of resting state functional brain networks in amyotrophic lateral sclerosis (ALS). J Neural Transm (Vienna) 19962021;128:1881–97 doi:10.1007/s00702-021-02413-0 pmid:34471976

    CrossRefPubMed
49. 49.↵
    1. Chiò A,
    2. Moglia C,
    3. Canosa A, et al

    . ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology 2020;94:e802–10 doi:10.1212/WNL.0000000000008869 pmid:31907290

    Abstract/FREE Full Text
50. 50.↵
    1. Finegan E,
    2. Chipika RH,
    3. Li Hi Shing S, et al

    . The clinical and radiological profile of primary lateral sclerosis: a population-based study. J Neurol 2019;266:2718–33 doi:10.1007/s00415-019-09473-z pmid:31325016

    CrossRefPubMed
51. 51.↵
    1. Tahedl M,
    2. Li H,
    3. Shing S,
    4. Finegan E, et al

    . Propagation patterns in motor neuron diseases: Individual and phenotype-associated disease-burden trajectories across the UMN-LMN spectrum of MNDs. Neurobiol Aging 2022;109:78–87 doi:10.1016/j.neurobiolaging.2021.04.03]1 pmid:34656922

    CrossRefPubMed